Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025
Are Vericel Corporation's (NASDAQ:VCEL) Mixed Financials Driving The Negative Sentiment?
Express News | Vericel Corp - Expects 100% Revenue From Domestic Sales in 2025 - SEC Filing
Express News | Vericel Corp - Anticipates Minimal Impact From New Tariffs - SEC Filing
BTIG Maintains Vericel(VCEL.US) With Buy Rating, Cuts Target Price to $60
Truist Financial Maintains Vericel(VCEL.US) With Buy Rating, Cuts Target Price to $51
Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 47% Undervaluation?
BTIG Maintains Vericel(VCEL.US) With Buy Rating, Maintains Target Price $63
Vericel to Present at Multiple Upcoming Investor Conferences
Truist Financial Maintains Vericel(VCEL.US) With Buy Rating, Announces Target Price $61
Truist Financial Maintains Vericel(VCEL.US) With Buy Rating
Truist Securities Cuts Price Target on Vericel to $61 From $67, Keeps Buy Rating
A Quick Look at Today's Ratings for Vericel(VCEL.US), With a Forecast Between $60 to $72
Analysts Offer Insights on Healthcare Companies: Vericel (VCEL), Radnet (RDNT) and Universal Health (UHS)
Truist Financial Remains a Buy on Vericel (VCEL)
Vericel Analyst Ratings
Vericel's Growth Potential: Expanding MACI Franchise and Burn Care Innovations Drive Buy Rating
Earnings Call Summary | Vericel(VCEL.US) Q4 2024 Earnings Conference
Analysts Are Bullish on Top Healthcare Stocks: Vericel (VCEL), Astria Therapeutics (ATXS)
Vericel | 10-K: FY2024 Annual Report